1. Lurain JR. Gestational trophoblastic disease I: epidemiology,
pathology, clinical presentation and diagnosis of gestational
trophoblastic disease, and management of hydatidiform mole.
Am J Obstet Gynecol. 2010;203(6):531-539.
2. Berkowitz RS, Goldstein DP. Clinical practice. Molar pregnancy. N Engl J Med. 2009;360(16):1639-1645.
3. Robbins SL, Kumar V, Cotran RS. Robbins and Cotran Pathologic
Basis of Disease. Saunders/Elsevier; 2010.
4. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic
disease. Lancet. 2010;376(9742):717-729.
5. Ngan HY, Kohorn EI, Cole LA, et al. Trophoblastic disease. Int
J Gynaecol Obstet. 2012;119(suppl 2):S130-S136.
WATANABE et al.
6. Powles T, Savage PM, Stebbing J, et al. A comparison of patients
with relapsed and chemo-refractory gestational trophoblastic
neoplasia. Br J Cancer. 2007;96(5):732-737.
7. Sato S, Yamamoto E, Niimi K, et al. The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and
actinomycin D in patients with choriocarcinoma and high-
risk gestational trophoblastic neoplasia. Int J Clin Oncol.
2020;25(1):203-209.
8. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9(1):28-39.
9. Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M. Opportunities
and challenges in phenotypic drug discovery: an industry perspective. Nat Rev Drug Discov. 2017;16(8):531-543.
10. Swinney DC. Phenotypic vs. target-based drug discovery for first-
in-class medicines. Clin Pharmacol Ther. 2013;93(4):299-301.
11. Jones LH, Bunnage ME. Applications of chemogenomic library screening in drug discovery. Nat Rev Drug Discov.
2017;16(4):285-296.
12. Takai N, Ueda T, Nishida M, Nasu K, Narahara H. Histone
deacetylase inhibitors induce growth inhibition, cell cycle arrest and apoptosis in human choriocarcinoma cells. Int J Mol
Med. 2008;21(1):109-115.
13. Kavanaugh SM, White LA, Kolesar JM. Vorinostat: a novel
therapy for the treatment of cutaneous T-cell lymphoma. Am J
Health Syst Pharm. 2010;67(10):793-797.
14. Pasini A, Marchetti C, Sissi C, et al. Novel polyamine-
naphthalene diimide conjugates targeting histone deacetylases and DNA for cancer phenotype reprogramming. ACS Med
Chem Lett. 2017;8(12):1218-1223.
15. Uehara N, Yoshizawa K, Tsubura A. Vorinostat enhances
protein stability of p27 and p21 through negative regulation
of Skp2 and Cks1 in human breast cancer cells. Oncol Rep.
2012;28(1):105-110.
16. Kawamata N, Chen J, Koeffler HP. Suberoylanilide hydroxamic
acid (SAHA; vorinostat) suppresses translation of cyclin D1 in
mantle cell lymphoma cells. Blood. 2007;110(7):2667-2673.
17. Marchion D, Münster P. Development of histone deacetylase
inhibitors for cancer treatment. Expert Rev Anticancer Ther.
2007;7(4):583-598.
18. Qian DZ, Wang X, Kachhap SK, et al. The histone deacetylase
inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater
antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/
ZK222584. Cancer Res. 2004;64(18):6626-6634.
19. Kumagai T, Wakimoto N, Yin D, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA)
profoundly inhibits the growth of human pancreatic cancer
cells. Int J Cancer. 2007;121(3):656-665.
20. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hy droxamic acid, an inhibitor of histone deacetylase, suppresses
the growth of prostate cancer cells in vitro and in vivo. Cancer
Res. 2000;60(18):5165-5170.
21. Nervi C, De Marinis E, Codacci-
Pisanelli G. Epigenetic
treatment of solid tumours: a review of clinical trials. Clin
Epigenetics. 2015;7:127.
22. Schneider BJ, Kalemkerian GP, Bradley D, et al. Phase I study
of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in
combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest New Drugs. 2012;30(1):249-257.
13
23. Haas NB, Quirt I, Hotte S, et al. Phase II trial of vorinostat in
advanced melanoma. Invest New Drugs. 2014;32(3):526-534.
24. Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis:
a regulated cell death nexus linking metabolism, redox biology,
and disease. Cell. 2017;171(2):273-285.
25. Magtanong L, Ko PJ, Dixon SJ. Emerging roles for lipids in non-
apoptotic cell death. Cell Death Differ. 2016;23(7):1099-1109.
26. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis:
an iron-
dependent form of nonapoptotic cell death. Cell.
2012;149(5):1060-1072.
27. Toyokuni S, Yanatori I, Kong Y, Zheng H, Motooka Y, Jiang L.
Ferroptosis at the crossroads of infection, aging and cancer.
Cancer Sci. 2020;111(8):2665-2671.
28. Zhang H, He Y, Wang JX, et al. miR-30-5p-mediated ferroptosis
of trophoblasts is implicated in the pathogenesis of preeclampsia. Redox Biol. 2020;29:101402.
29. Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS,
Stockwell BR. Peroxidation of polyunsaturated fatty acids
by lipoxygenases drives ferroptosis. Proc Natl Acad Sci USA.
2016;113(34):E4966-E4975.
30. Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1-2):317-331.
31. Seibt TM, Proneth B, Conrad M. Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic Biol Med.
2019;133:144-152.
32. Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA.
Identification of the NF-E2-related factor-2-dependent genes
conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol
Chem. 2003;278(14):12029-12038.
33. Kerins MJ, Ooi A. The roles of NRF2 in modulating cellular iron
homeostasis. Antioxid Redox Signal. 2018;29(17):1756-1773.
34. Wu KC, Cui JY, Klaassen CD. Beneficial role of Nrf2 in regulating NADPH generation and consumption. Toxicol Sci.
2011;123(2):590-600.
35. Lee C. Collaborative power of Nrf2 and PPARγ activators
against metabolic and drug-induced oxidative injury. Oxid Med
Cell Longev. 2017;2017:1378175.
36. Sun X, Ou Z, Chen R, et al. Activation of the p62-Keap1-NRF2
pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63(1):173-184.
37. Roh JL, Kim EH, Jang H, Shin D. Nrf2 inhibition reverses the
resistance of cisplatin-resistant head and neck cancer cells to
artesunate-induced ferroptosis. Redox Biol. 2017;11:254-262.
38. Ma X, Zhang J, Liu S, Huang Y, Chen B, Wang D. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer. Cancer Chemother
Pharmacol. 2012;69(2):485-494.
39. Homma S, Ishii Y, Morishima Y, et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res. 2009;15(10):3423-3432.
40. Lister A, Nedjadi T, Kitteringham NR, et al. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation
and therapy. Mol Cancer. 2011;10:37.
41. Wu Y, Zhang S, Gong X, et al. The epigenetic regulators and
metabolic changes in ferroptosis-associated cancer progression.
Mol Cancer. 2020;19(1):39.
42. Zhang T, Sun B, Zhong C, et al. Targeting histone deacetylase
enhances the therapeutic effect of Erastin-induced ferroptosis
14 43. 44. 45. 46. 47. 48. 49. in EGFR-activating mutant lung adenocarcinoma. Transl Lung
Cancer Res. 2021;10(4):1857-1872.
Sato H, Tamba M, Ishii T, Bannai S. Cloning and expression of a plasma membrane cystine/glutamate exchange
transporter composed of two distinct proteins. J Biol Chem.
1999;274(17):11455-11458.
Sato H, Tamba M, Kuriyama-Matsumura K, Okuno S, Bannai
S. Molecular cloning and expression of human xCT, the light
chain of amino acid transport system xc. Antioxid Redox Signal.
2000;2(4):665-671.
Zhang L, Huang Y, Ling J, et al. Overexpression of SLC7A11: a
novel oncogene and an indicator of unfavorable prognosis for
liver carcinoma. Future Oncol. 2018;14(10):927-936.
Timmerman LA, Holton T, Yuneva M, et al. Glutamine sensitivity
analysis identifies the xCT antiporter as a common triple-negative
breast tumor therapeutic target. Cancer Cell 2013, 24(4):450–465.
Ji X, Qian J, Rahman SMJ, et al. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer
progression. Oncogene. 2018;37(36):5007-5019.
Koppula P, Zhang Y, Zhuang L, Gan B. Amino acid transporter
SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun
(Lond). 2018;38(1):12.
Nakamura E, Sato M, Yang H, et al. 4F2 (CD98) heavy chain
is associated covalently with an amino acid transporter and
WATANABE et al.
controls intracellular trafficking and membrane topology of
4F2 heterodimer. J Biol Chem. 1999;274(5):3009-3016.
50. Shin CS, Mishra P, Watrous JD, et al. The glutamate/cystine
xCT antiporter antagonizes glutamine metabolism and reduces
nutrient flexibility. Nat Commun. 2017;8:15074.
5 1. Wang X, Liu K, Gong H, et al. Death by histone deacetylase
inhibitor quisinostat in tongue squamous cell carcinoma via
apoptosis, pyroptosis, and ferroptosis. Toxicol Appl Pharmacol.
2021;410:115363.
SUPPORTING INFORMATION
Additional supporting information can be found online
in the Supporting Information section at the end of this
article.
How to cite this article: Watanabe E, Yokoi A,
Yoshida K, et al. Drug library screening identifies
histone deacetylase inhibition as a novel therapeutic strategy for choriocarcinoma. Cancer Med.
2022;00:1-14. doi: 10.1002/cam4.5243
...
論文の公開元へ
